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Abstract: On February 2, 2012, the National Cancer Institute 
(NCI) sponsored a 2-day workshop with the NCI Thoracic 
Malignancies Steering Committee and the Food and Drug 
Administration to bring together leading academicians, clini-
cians, industry and government representatives to identify chal-
lenges and potential solutions in the clinical development of 
novel targeted therapies for lung cancer. Measures of success are 
rapidly evolving from a scientific and regulatory perspective and 
the objectives of this workshop were to achieve initial consensus 
on a high priority biomarker-driven clinical trial designed to rap-
idly assess the activity of targeted agents in molecularly defined 
lung cancer subsets and to facilitate generation of data leading 
to approval of these new therapies. Additionally, the meeting 
focused on identification of the barriers to conduct such a trial 
and the development of strategies to overcome those barriers. 
The “Lung Master Protocols” recently launched by NCI were the 
direct outcome of this workshop.
Key Words: NCI/FDA workshop leading to the Inception of "Master 
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Despite rapid progress in identifying molecular abnor-malities driving lung cancer, this has not yet been trans-
lated into improvement in long-term outcome for patients.1 
Treatment for non–small-cell lung cancer (NSCLC) that com-
prises about 80% of the lung cancer cases is shifting toward 
regimens targeting relatively uncommon molecular alterations 
rather than traditional histologic subtypes.2 This new complex-
ity raises patient selection, accrual and funding challenges, so 
new more efficient approaches are essential.3
The predominance of negative Phase III trials4,5 con-
ducted in unselected patient populations and the recent findings 
that the majority of NSCLC patients’ tumors harbor molecular 
“drivers” are changing the paradigm for rapid clinical develop-
ment of new therapies.6 By incorporating potential biomarkers 
and assessing pharmacokinetic (PK)/pharmacodynamic (PD) 
effects, the next generation of early clinical trials can quickly 
establish agent activity with smaller sample sizes resulting in 
rapid and cost-effective biomarker-driven development.
While the potential utility of “companion” diagnostics 
opens the door to optimal patient selection,7 rapid development 
is hindered by intratumoral heterogeneity, low frequency of 
responsible driver mutations, and the variety of tests available 
to assess each potential target (analyte).8 The limited amount 
of tissue available for diagnostic use and the high costs of indi-
vidual tests mean that sequential individual tests are not likely 
to be feasible and that multiplexed assays or next-generation 
DNA sequencing may be required. 
TRIAL DESIGN ISSUES
A biomarker used in a clinical trial can be prognostic 
or predictive, and it is important to distinguish between these 
two types of biomarkers. A prognostic biomarker is associated 
with how well patients will do with a given treatment. A pre-
dictive biomarker predicts what therapy will work best for an 
individual patient. Predictive biomarkers tend to be more use-
ful because they can improve outcomes for patients by opti-
mizing choice of treatment. For a single predictive biomarker, 
there are various trial designs that can be considered.6,9–11 The 
Consensus Report of a Joint NCI Thoracic Malignancies 
Steering Committee: FDA Workshop on Strategies for 
Integrating Biomarkers into Clinical Development of New 
Therapies for Lung Cancer Leading to the Inception of 
“Master Protocols” in Lung Cancer
Shakun M. Malik, MD,* Richard Pazdur, MD,† Jeffrey S. Abrams, MD,* Mark A. Socinski, MD,‡  
William T. Sause, MD,§ David H. Harpole Jr., MD,║ John J. Welch, MD, PhD,* Edward L. Korn, PhD,¶ 
Claudio Dansky Ullmann, MD,* and Fred R. Hirsch, MD PhD#
DOI: 10.1097/JTO.0000000000000314.
Copyright © 2014 by the International Association for the Study of Lung Can-
cer. This is an open-access article distributed under the terms of the Creative 
Commons Attribution-Non Commercial-No Derivatives 3.0 License, where it 
is permissible to download and share the work provided it is properly cited. The 
work cannot be changed in any way or used commercially.
ISSN: 1556-0864/14/0910-1443
*Clinical Investigations Branch, Cancer Therapy Evaluation Program, National 
Cancer Institute, National Institutes of Health, Bethesda, MD; †Offices 
of Hematology and Oncology Products, Center for Drug Evaluation 
and Research U.S. Food and Drug Administration, Silver Spring, MD; 
‡University of Pittsburgh Medical Center, Pittsburgh, PA; §University of 
Utah, Salt Lake City, UT; ║Duke University Medical Center, Durham, 
NC; ¶Biometric Research Branch, Cancer Therapy Evaluation Program, 
National Cancer Institute, National Institutes of Health, Bethesda, MD; 
and #University of Colorado, School of Medicine, Denver, CO.
Address correspondence to: Shakun M. Malik, Cancer Therapy Evaluation 
Program, National Cancer Institute, National Institutes of Health, 
Bethesda, MD 20850. E-mail: shakun.malik@nih.gov
SPECIAL ARTICLE
Open access under CC BY-NC-ND license.
1444 Copyright © 2014 by the International Association for the Study of Lung Cancer
Malik et al. Journal of Thoracic Oncology ®  •  Volume 9, Number 10, October 2014
appropriate trial design and analysis strategy should depend 
on the preexisting evidence that the biomarker can success-
fully identify patients who will benefit from the treatment.12 
If one is confident that the targeted therapy will not work in 
the biomarker-negative population, then an enrichment design 
(also known as a targeted design or a marker-positive design), 
which only enrolls and randomizes patients who are posi-
tive for the biomarker can be used. For example, crizotinib 
was tested versus standard chemotherapy in NSCLC patients 
with alteration in anaplastic lymphoma kinase (ALK) gene.13 
If one is less confident about the biomarker’s predictive abil-
ity, then a biomarker-stratified design (also known as an all-
comers design) in which all patients are randomized can be 
used. With this design, the treatment effect can be assessed 
in both the biomarker-positive and biomarker-negative patient 
populations. For example, the trial BR.21 examined epider-
mal growth factor receptor (EGFR) expression status (in 
the patients for whom tumor tissue was available) and the 
effectiveness of erlotinib in NSCLC.14 One can also exam-
ine the effect of treatment overall not taking into account the 
biomarker in the all-comers design; this is a traditional ran-
domized trial design. A third design, the biomarker strategy 
design, randomizes patients between a control treatment and 
a treatment that is chosen for each patient on the basis of his 
or her biomarker status. An example is the trial conducted by 
the Spanish Lung Cancer Group in which NSCLC patients 
were randomized between a control arm of docetaxel/cispla-
tin and an experimental arm of either docetaxel/cisplatin or 
docetaxel/gemcitabine based on their ERCC1 mRNA levels.15 
The biomarker strategy design can be inefficient because 
many patients on both treatment arms may receive the same 
treatment; it is generally not recommended unless all (or 
almost all) the patients on the experimental treatment arm will 
receive many different treatments that are not the same as the 
control-arm treatment.
When there is more than one biomarker or more than 
one targeted therapy of interest, the trial designs and analyses 
can become more complicated. For example, one can combine 
an enrichment design with a biomarker-stratified design such 
as in the TAILOR trial.16 With multiple possible biomark-
ers (or high-dimensional genomic data), cross-validation in 
which combinations of markers are developed on subsets of 
the data and their predictive ability tested on other subsets of 
the data can be useful to guard against overfitting the data.17 
When there are multiple targeted treatments, for example, in 
the BATTLE-1 trial18 and the I-SPY2 trial,19 the analyses of 
the trials can be considered exploratory. For a study with the 
potential to lead to agent registration, it is critical to have a 
matched control arm for each substudy to permit compara-
tive assessment of efficacy and toxicity. It is desirable to have 
interim monitoring and analysis plans incorporated in clini-
cal trials so that treatment arms that are not promising can be 
dropped early. Outcome-adaptive randomization is a different 
design strategy that aims to put more patients on better per-
forming treatment arms. However, it is complex to implement 
and requires a meaningful short-term clinical end point and a 
fast turnaround for biomarker assays. Potential disadvantages 
of outcome-adaptive randomization designs are that they may 
produce biased results if the prognostic characteristics of 
patients entering the trial change over the period of accrual, 
and they may lead to a larger total sample size than simpler 
interim monitoring methods, potentially resulting in a greater 
absolute number of patients having bad outcomes.20,21
Regardless of the incorporation of a biomarker, trial 
designs need end points relevant to the questions being asked. 
Traditionally, the efficacy end point of trials leading to Food 
and Drug Administration (FDA) approval of therapies in 
lung cancer has been overall survival (OS), but progression-
free survival (PFS) is gaining importance as a primary end 
point. The growing popularity of crossover designs and the 
increasing availability of multiple lines of therapy have largely 
undermined OS as a sole definitive end point. Nonetheless, 
assessment of OS is still critical even when there are effective 
subsequent therapies.22
PFS results should be statistically significant and clini-
cally meaningful, and ideally should be associated with an 
improvement in patient reported outcomes and Quality of 
Life. What is clinically meaningful to patients will depend on 
the clinical stage of their cancer and the toxicity of the drug. 
For example, a patient with early stage lung cancer receiv-
ing adjuvant therapy with intention to achieve a cure may be 
willing to accept a higher level of toxicity than a patient who 
is receiving the therapy in a metastatic setting where cure is 
not possible. There are no FDA-approved patient reported 
outcomes and Quality of Life tools for lung cancer and the 
development and validation of these tools is urgently needed.
REGULATORY CHALLENGES
Many regulatory challenges have arisen as a result of 
increased knowledge of the molecular aberrations in lung 
cancer and subsequent development of novel agents to tar-
get these abnormalities. There has been a tendency by drug 
developers and investigators toward overly strict interpre-
tation of the regulations and a general reluctance to change 
current practice for fear of adverse regulatory consequences. 
The trials submitted sometimes require excessive data collec-
tion and may be poorly designed (e.g., too complicated or too 
many objectives). Earlier and more continuous engagement 
between regulatory authorities and pharmaceutical and diag-
nostic industry partners are crucial for success in this rapidly 
developing field.
FDA regulations state that approval should be based 
on two adequate and well-controlled studies. A single study 
may be acceptable to the FDA if it is a large multicenter study 
where one or a few institutions did not contribute a dispro-
portionate number of patients, it has consistency among vari-
ous subsets, and it has multiple end points evaluated such as 
response rate, PFS, and OS such that the findings are robust 
with clinically and statistically persuasive outcomes.
An optimal drug/device co-development plan requires 
simultaneous development of biomarker assay methodology 
and clinical trials to determine drug efficacy. Clinical data for 
biomarker development can come from retrospective or pro-
spective clinical trials.23 Retrospective trial analysis requires 
that adequate biomarker specimens were collected in most 
of the study patients and analyzed according to a prespeci-
fied plan.24 The advantages of retrospective analysis include 
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availability of adequate follow-up, the inclusion of patients 
with biomarker-positive and biomarker-negative cancers in 
the data set, and a cost savings over conducting an additional 
prospective trial. Disadvantages include multiplicity issues in 
biomarker selection and, depending on assay requirements, 
the possibility of inadequate specimen collection, handling, 
or storage. In addition, a confirmatory trial will still likely be 
needed as retrospective trial data are often incomplete.
In contrast to retrospective analyses, a prospective trial 
requires early development of an in vitro diagnostic to iden-
tify the presence or absence of a specific predictive biomarker. 
All study patients will have known biomarker status before 
randomization and biomarker status can be used as a stratifi-
cation variable. Both biomarker-positive and biomarker-neg-
ative patients should be enrolled if it is desired to determine 
whether the biomarker and its assay are truly predictive.
Ideally, the tissue sample should be obtained as close 
to the time of treatment as possible because a patient’s can-
cer may develop new competitive advantage and/or resistance 
mutations over time. However, this may not be always pos-
sible due to the morbidities and the cost associated with biop-
sies. As might be expected, tissue often runs out before all 
the planned later assays can be performed and may require 
biomarker prioritization.
Pharmaceutical industry representatives at the meeting 
discussed their challenges. These include the global burden of 
developing drugs, establishing unmet medical need in a newly 
defined molecular group, differences in the evidence required 
for US and EU accelerated/conditional approval, and the costs 
of companion diagnostic development. In addition, when 
there is preliminary evidence of promising efficacy, not allow-
ing crossover has been found to be unacceptable to investiga-
tors and patients.
DRUG AND BIOMARKER CO-DEVELOPMENT  
IN LUNG CANCER
Biomarker-targeted drug development presents oppor-
tunities for “personalized medicine,” although clinical trial 
design is complicated by the need to address simultaneously 
both diagnostics and treatment. Well-planned development 
and evaluation of the diagnostic device is essential to under-
standing its value in guiding use of the therapeutic product. 
Clinicians will rely on this test information to help make criti-
cal treatment decisions.
A clinical assay is a system that includes both preana-
lytical treatment of the specimen (i.e., how the specimen is 
obtained, stored, shipped, and preprocessed for the assay) 
and conduct of the assay itself, which includes monitor-
ing for quality and reproducibility and the methods for data 
capture, assessment, and reporting. A clinical assay must be 
demonstrated to perform reproducibly in the intended clinical 
environment.
Biomarker testing should be standardized and reproduc-
ible, should have a quick enough turnaround time to be use-
ful for clinical decision-making, should be cost-effective, and 
ideally should involve little risk to patients.
Concerns regarding the availability of tissue needed to 
test for multiple markers and the time lost to treat patients 
while testing different markers are being addressed by the cur-
rent effort to develop multiplex assays that interrogate mul-
tiple signaling pathways. Approval of these assays by the FDA 
will require proper validation.25,26
LESSONS LEARNED: PERSPECTIVES  
MOVING FORWARD
Bevacizumab was approved by the FDA for the first-
line therapy of advanced nonsquamous NSCLC based on a 
modest survival benefit noted in a Phase III study E4599.27 
However, several other agents that target the angiogenic path-
way have not demonstrated therapeutic benefit in NSCLC. 
The main problem has been the lack of a predictive biomarker 
that could identify patients who stand to benefit. None of the 
biomarkers tested to date have consistently demonstrated pre-
dictive potential. The panel concluded that in the absence of a 
promising biomarker, conducting further large trials with anti-
angiogenic agents in NSCLC is not warranted.
The development of EGFR inhibitors represents a remark-
able tale of drug development followed by identification of a 
predictive biomarker.28–33 As new EGFR inhibitors are devel-
oped, the main areas of need are to improve upon the efficacy 
of existing agents, to delay the emergence of resistance, and to 
overcome resistance. It will be important to obtain tumor tis-
sues in clinical trials of EGFR inhibitors to conduct biomarker 
studies that will enhance our knowledge regarding resistance 
pathways. As the importance of developing biomarkers is clear, 
physicians should be open to obtaining a tumor biopsy at vari-
ous time points during the course of the treatment of lung can-
cer. The BATTLE study showed that such an approach could aid 
in development of individualized treatment approaches. There 
is a need to adopt standard practices for specimen preparation 
and storage in order to obtain maximal yield from the biopsy.
Increasingly, clinical trials require archived tumor spec-
imens and in some instances, fresh frozen tumor tissue, as 
part of the evaluation of new agents. This represents a chal-
lenge to trial patient accrual through community oncology 
practices. In addition to logistical challenges, such procedures 
are often not compensated adequately by the study sponsor or 
payers. Standardized specimen acquisition and storage prac-
tices are also necessary to ensure submission of high-quality 
specimens from the community setting. The panel agreed that 
community sites would greatly benefit from guidance on these 
important issues in order to increase the proportion of patients 
enrolled to lung cancer trials.
 As clinical trials move toward patient selection based 
on predictive biomarkers, patients with cancers negative for 
these markers are often excluded. This causes anxiety and dis-
appointment for patients who are unable to participate in clini-
cal trials of exciting new agents. It will be important to allow 
for testing promising drugs in biomarker-negative patients, 
provided there is an appropriate scientific rationale. Another 
possibility is to include patients without the biomarker in a 
concurrent trial of a non-targeted agent. This will enhance 
patient enthusiasm about participation in such clinical trials.
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DEVELOPMENT OF FUTURE LUNG  
CANCER TRIALS
A number of controversies remain including how to 
prioritize treatment arms, when there are multiple, targeted 
agents, and how to select a combination of two targeted agents 
versus the addition of targeted agents to conventional therapy 
such as cytotoxic chemotherapy and/or radiotherapy.
The panel agreed that future proposals should result in a 
paradigm shift, be biologically based with innovative designs 
and that patients should be selected based upon molecular 
characteristics if progress in NSCLC is to occur. There was 
general agreement regarding the desire to integrate validated 
biomarkers into future clinical trial designs, to include assess-
ment of toxicity in conjunction with pharmacogenomics, to 
validate imaging as an early indicator of treatment effective-
ness, and to assess the utility of serial biopsies whenever 
possible, particularly at the time of clinical or radiographic 
progression.
The panel was asked to consider three overriding ques-
tions when evaluating a proposal presented: (1) Is the proposal 
novel and feasible? (2) Are the study end points indicative of 
adequate clinical benefit and are the statistical underpinnings 
of the trial robust? (3) Is there adequate evidence to support 
the use of a predictive biomarker and are the selected assays 
appropriately validated?
Concepts presented included first-in-man targets to be 
studied with response rate as end point, combination chemo/
radiation trials for locally advanced lung cancers, and target-
based adjuvant trials. An adaptive trial for patients with region-
ally advanced NSCLC was discussed by RTOG. The proposal 
would test chemoradiation following the appropriate molecu-
lar-targeted agent (EGFR mutated or ALK-positive patients).
Two adjuvant trials (stages I–III) were discussed, one pro-
posed by ECOG (Now ECOG-ACRIN) in patients with ALK 
gene rearrangements to study crizotinib with an end point of 
disease-free survival (DFS) and a similar trial proposed by 
CALGB (now Alliance) in patients with EGFR mutations to 
study erlotinib with an end point of OS. It was noted that a large 
number of patients would need to be screened, but only about 
5% to 15% of screened patients would be enrolled in each trial 
making upwards of 85% of the screened specimens irrelevant. A 
call was made by the attendees to combine the efforts to employ 
a common screening step with central testing and the provision 
to add study arms in future. The outcome of this discussion is 
the current design of ALCHEMIST (Adjuvant Lung Cancer 
Enrichment Marker Identification and Sequencing Trial).
The ALCHEMIST trial will enroll patients with resect-
able (stage IB ≥ 4 cm, II and IIIA) adenocarcinoma of the 
lung, with OS as the primary end point (Figure 1).
In an umbrella screening protocol A151216, patients’ 
tumors will be screened for EGFR mutations using a poly-
merase chain reaction-based assay and ALK fusion altera-
tions using the FDA-approved break-apart fluorescence in situ 
hybridization assay. If genetic alterations are detected in their 
tumors, these patients will be eligible for separate adjuvant 
studies A081105 comparing the addition of erlotinib (for acti-
vating EGFR mutations) or E4512 adding crizotinib (for ALK 
fusions) after standard treatment versus standard treatment 
and placebo. Patients will receive protocol therapy for up to 
2 years unless development of unresolved toxicities, patient 
withdrawal or physician decides to stop the therapy in the best 
interest of the patient. In order to enroll 410 patients in two 
arms of erlotinib versus placebo and 300 in crizotinib versus 
Placebo, it is estimated that about6000 to 8000 patients will be 
needed to enroll in screening protocol. All patients, including 
those who discontinue protocol therapy early, will be followed 
for survival for 10 years from the date of registration.
Patients whose tumors lack these alterations will enroll 
in a registry study and their tumors will undergo whole-exome 
sequencing. If they should relapse, every attempt will be made 
to re-sequence their tumor DNA at that time to determine the 
natural genomic history of these cancers.
To accelerate development of biomarker-driven tri-
als, attendees agreed that it is critical to enhance coordina-
tion between pharmaceutical developers, FDA, academic 
and community-based clinical investigators, National Cancer 
Institute (NCI), and patients with the intention to decrease 
red tape, reduce competition, and enhance cooperation across 
both commercial and academic clinical trials organizations. 
I-SPY was cited as an example of such collaborative effort 
currently ongoing in patients with breast cancer. There was a 
consensus to reward participation and teamwork and to create 
a mechanism to eliminate competition among investigators.
In conclusion, the development of “Master Protocols” 
for different stages of lung cancer (adjuvant, neoadjuvant, 
stage III, advanced/metastatic) was identified as the most 
expeditious way to cut down the time and effort needed to test 
new agents. Extensive collaboration between the FDA, NCI, 
academia, community oncology programs, and the pharma-
ceutical industry is the key to developing such complex trials 
but the effort could be rewarded with more scientifically rel-
evant trials that are attractive to patients and thus lead to more 
rapidly completed trials. This approach could revolutionize 
lung cancer treatment by bringing forward new drugs much 
Screening Trial  (A151216)
Pre-op patients Post-op patients
Surgery
EGFR activating mutation
A081105 ALK gene alterationsE4512
Follow up to 
recurrence or 
5-years   
Central CLIA-Lab Marker Analysis  
Final Eligibility review 
EGFR and ALK
Negative
Biopsy at recurrence if deemed necessary by the treating 
physician. If tissue left over will be utilized for research
Erlotinib vs. Placebo X 2yrs
Primary End Point=OS
Crizotinib vs. Placebo X 2yrs
Primary End Point=OS
Patients will 
complete standard 
chemotherapy  with 
or without radiation 
therapy as per their 
physicians 
recommendations 
prior to the study 
drug
This is a collaborative 
effort by NCI/Alliance 
and ECOG/ACRIN
Trials will be available 
to patient enrollment 
for the members of the 
NCI-sponsored 
National Clinical Trials 
Network (NCTN) 
FIGURE 1.  ALCHEMIST study schema. ALCHEMIST—
A151216, screening trial; ALCHEMIST—EGFR A081105, 
erlotinib treatment arm; ALCHEMIST—ALK E4512, crizotinib 
treatment arm.
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more rapidly for approval and eventually leading to improved 
outcomes for patients.
The NCI “Master Protocol” Phase II/III trial for second-
line treatment of squamous lung cancer, the Lung-MAP trial, 
is attempting such a novel approach. In this trial, patients 
will be screened for sets of specific molecular abnormalities 
identified by a combination of a customized next-generation 
DNA sequencing mutation panel and immunohistochemistry 
assays. For each set of abnormalities corresponding to targeted 
pathway, patients will be randomly assigned to new targeted 
therapy or standard therapy based on designated therapeutic 
biomarker–drug combinations for each biomarker-driven sub-
study. Patients whose tumors lack these specific abnormalities 
will be assigned to a “non-match” arm and will be randomly 
assigned to an immunotherapy agent versus standard chemo-
therapy. Each substudy will function autonomously and will 
open and close independently of the other substudies. The can-
didate drugs must have demonstrated biologic activity against 
the target associated with a proposed predictive biomarker(s). 
The primary objective within the Phase II component of each 
substudy is to evaluate whether there is sufficient evidence to 
continue to the Phase III component of the substudy by com-
paring PFS. Phase III components of the study has PFS as 
primary end point that has been prespecified to not only be sta-
tistically significant but also clinically meaningful (Figure 2).
The goal of this trial is to expeditiously provide evidence 
of agent efficacy to support FDA approval of new therapies in 
order to ultimately benefit patients.
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